Literature DB >> 21050790

[Reporting and notification of transfusion serious adverse events in France].

G Daurat1.   

Abstract

Surveillance of serious adverse events in transfusion has recently been enforced in all European Union member states, and in France in 2007. This is an important expansion of the field of haemovigilance towards risk management in transfusion from donor selection to recipients follow up. Participation in this notification system is mandatory for all health professionals. They have to report immediately all serious adverse events to the haemovigilance officer of their hospital or transfusion centre. In accordance with a national procedure, the latter has to notify all serious adverse events to regional and national competent authorities using a web-based application. They also have to perform a root case analysis and propose corrective measures. However, as the definition of the seriousness of adverse events is still imprecise, there is a dramatic heterogeneity in the notification level among regions. Therefore, basic criteria of evaluation of surveillance systems, such as sensitivity or representativeness, are not fulfilled. Next step will be the introduction of a more precise definition of seriousness, through a list of events to be notified, in order to achieve a quality level similar to that of transfusion adverse reactions surveillance.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21050790     DOI: 10.1016/j.tracli.2010.09.150

Source DB:  PubMed          Journal:  Transfus Clin Biol        ISSN: 1246-7820            Impact factor:   1.406


  2 in total

1.  The role of hemovigilance as a mechanism to increase transfusion safety.

Authors:  Hélio Moraes-Souza
Journal:  Rev Bras Hematol Hemoter       Date:  2011

2.  Analysis of Adverse Reactions of Blood Transfusion and Discussion of Influencing Factors in Linyi Area from 2013 To 2020.

Authors:  Xiuping Zhang; Yanli Zhang; Cao Qi; Chunling Ma
Journal:  Iran J Public Health       Date:  2021-07       Impact factor: 1.429

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.